Tags

Type your tag names separated by a space and hit enter

Oral contraceptives in diabetic women: metabolic effects of four compounds with different estrogen/progestogen profiles.
Fertil Steril. 1986 Nov; 46(5):858-64.FS

Abstract

The metabolic effects of four oral contraceptives with different estrogen/progestogen profiles (monophasic nonalkylated estrogen/norethindrone, low-dose monophasic ethinyl estradiol (EE2)/norethindrone, progestogen only treatment with norethindrone, and triphasic EE2/levonorgestrel) were examined in insulin-dependent diabetic women. During the 6-month study period, no differences were found in fasting plasma glucose, 24-hour insulin requirements, glycated hemoglobin, free fatty acids, low-density lipoprotein cholesterol concentrations, or high-density lipoprotein cholesterol/total cholesterol ratio between the patients in each treatment group. Compared with the nonalkylated estrogen/norethindrone and the triphasic EE2/levonorgestrel formulations, the low-dose EE2/norethindrone combination resulted in small but significant increases in plasma triglyceride and very low-density lipoprotein cholesterol levels (P less than 0.01), which seemed unfavorable from a clinical point of view. Norethindrone-only treatment appeared to be an appropriate alternative to both the nonalkylated estrogen/norethindrone combination and the triphasic EE2/levonorgestrel formulations.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

3781003

Citation

Skouby, S O., et al. "Oral Contraceptives in Diabetic Women: Metabolic Effects of Four Compounds With Different Estrogen/progestogen Profiles." Fertility and Sterility, vol. 46, no. 5, 1986, pp. 858-64.
Skouby SO, Mølsted-Pedersen L, Kühl C, et al. Oral contraceptives in diabetic women: metabolic effects of four compounds with different estrogen/progestogen profiles. Fertil Steril. 1986;46(5):858-64.
Skouby, S. O., Mølsted-Pedersen, L., Kühl, C., & Bennet, P. (1986). Oral contraceptives in diabetic women: metabolic effects of four compounds with different estrogen/progestogen profiles. Fertility and Sterility, 46(5), 858-64.
Skouby SO, et al. Oral Contraceptives in Diabetic Women: Metabolic Effects of Four Compounds With Different Estrogen/progestogen Profiles. Fertil Steril. 1986;46(5):858-64. PubMed PMID: 3781003.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oral contraceptives in diabetic women: metabolic effects of four compounds with different estrogen/progestogen profiles. AU - Skouby,S O, AU - Mølsted-Pedersen,L, AU - Kühl,C, AU - Bennet,P, PY - 1986/11/1/pubmed PY - 1986/11/1/medline PY - 1986/11/1/entrez KW - Anthropometry KW - Biology KW - Body Weight KW - Cholesterol KW - Clinical Research KW - Comparative Studies KW - Contraception KW - Contraceptive Agents KW - Contraceptive Agents, Female KW - Contraceptive Methods--side effects KW - Denmark KW - Developed Countries KW - Diabetes Mellitus KW - Diseases KW - Economic Factors KW - Endocrine Effects KW - Endocrine System KW - Estrogens KW - Ethinyl Estradiol KW - Europe KW - Family Planning KW - Growth KW - Hormones KW - Ingredients And Chemicals KW - Levonorgestrel KW - Lipid Metabolic Effects KW - Lipids KW - Norethindrone KW - Northern Europe KW - Oral Contraceptives, Combined--side effects KW - Oral Contraceptives, Low-dose--side effects KW - Oral Contraceptives--side effects KW - Organic Chemicals KW - Physiology KW - Reproductive Control Agents KW - Research And Development KW - Research Methodology KW - Scandinavia KW - Studies KW - Technology KW - Treatment SP - 858 EP - 64 JF - Fertility and sterility JO - Fertil Steril VL - 46 IS - 5 N2 - The metabolic effects of four oral contraceptives with different estrogen/progestogen profiles (monophasic nonalkylated estrogen/norethindrone, low-dose monophasic ethinyl estradiol (EE2)/norethindrone, progestogen only treatment with norethindrone, and triphasic EE2/levonorgestrel) were examined in insulin-dependent diabetic women. During the 6-month study period, no differences were found in fasting plasma glucose, 24-hour insulin requirements, glycated hemoglobin, free fatty acids, low-density lipoprotein cholesterol concentrations, or high-density lipoprotein cholesterol/total cholesterol ratio between the patients in each treatment group. Compared with the nonalkylated estrogen/norethindrone and the triphasic EE2/levonorgestrel formulations, the low-dose EE2/norethindrone combination resulted in small but significant increases in plasma triglyceride and very low-density lipoprotein cholesterol levels (P less than 0.01), which seemed unfavorable from a clinical point of view. Norethindrone-only treatment appeared to be an appropriate alternative to both the nonalkylated estrogen/norethindrone combination and the triphasic EE2/levonorgestrel formulations. SN - 0015-0282 UR - https://www.unboundmedicine.com/medline/citation/3781003/Oral_contraceptives_in_diabetic_women:_metabolic_effects_of_four_compounds_with_different_estrogen/progestogen_profiles_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0015-0282(16)49825-0 DB - PRIME DP - Unbound Medicine ER -